AngioDynamics Q2 Results Top Estimates; Boosts FY26 Net Sales Outlook

Core Viewpoint - AngioDynamics, Inc. maintains its adjusted loss guidance for fiscal 2026 while raising its annual net sales outlook Financial Performance - For fiscal 2026, the company projects an adjusted loss in the range of $0.33 to $0.23 per share, while raising net sales guidance to between $312 million and $314 million from the previous forecast of $308 million to $313 million [1] - Analysts expect the company to report a loss of $0.33 per share on net sales of $310.27 million for the year [2] - In the second quarter, the company reported a net loss of $6.35 million or $0.15 per share, compared to a loss of $10.74 million or $0.26 per share in the same quarter last year [2] - Adjusted earnings for the quarter were $0.00 per share, compared to an adjusted loss of $0.04 per share in the year-ago quarter [2] - Net sales for the quarter increased to $79.43 million from $72.85 million in the same quarter last year [3] Market Expectations - The Street anticipated a loss of $0.10 per share on net sales of $76.43 million for the quarter [4] Leadership Changes - Jim Clemmer, the President and CEO, intends to retire upon the appointment of a successor, expected during fiscal 2027, with a search committee established to find the next CEO [4]